Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes

• Verfasst von: Althammer, Ferdinand [VerfasserIn]
• Verfasst von: Muscatelli, Françoise [VerfasserIn]
• Verfasst von: Grinevich, Valéry [VerfasserIn]
• Verfasst von: Schaaf, Christian P. [VerfasserIn]
• Titel: Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes
• Titelzusatz: evidence, disappointments, and future research strategies
• Verf.angabe: Ferdinand Althammer, Francoise Muscatelli, Valery Grinevich, Christian P. Schaaf
• E-Jahr: 2022
• Jahr: 08 August 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 03.03.2023
• Titel Quelle: Enthalten in: Translational Psychiatry
• Ort Quelle: London : Nature Publishing Group, 2011
• Jahr Quelle: 2022
• Band/Heft Quelle: 12(2022), Artikel-ID 318, Seite 1-11
• ISSN Quelle: 2158-3188
• DOI: doi:10.1038/s41398-022-02054-1
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Autism spectrum disorders
• Sach-SW: Medical genetics
• Sach-SW: Molecular neuroscience
• K10plus-PPN: 1838104321
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

The prosocial neuropeptide oxytocin is being developed as a potential treatment for various neuropsychiatric disorders including autism spectrum disorder (ASD). Early studies using intranasal oxytocin in patients with ASD yielded encouraging results and for some time, scientists and affected families placed high hopes on the use of intranasal oxytocin for behavioral therapy in ASD. However, a recent Phase III trial obtained negative results using intranasal oxytocin for the treatment of behavioral symptoms in children with ASD. Given the frequently observed autism-like behavioral phenotypes in Prader-Willi and Schaaf-Yang syndromes, it is unclear whether oxytocin treatment represents a viable option to treat behavioral symptoms in these diseases. Here we review the latest findings on intranasal OT treatment, Prader-Willi and Schaaf-Yang syndromes, and propose novel research strategies for tailored oxytocin-based therapies for affected individuals. Finally, we propose the critical period theory, which could explain why oxytocin-based treatment seems to be most efficient in infants, but not adolescents.